Our data demonstrate for the first time that the high CDK4 activity in MCL is a prerequisite for the response to bortezomib therapy as well as for other compounds that require stabilization of NOXA for efficient cell death induction. This evidence concerns the gene PMAIP1 and mantle cell lymphoma.